New injection shows promise for relieving intense itching
NCT ID NCT06424470
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether Stapokibart injection can reduce severe itching and skin bumps in adults with prurigo nodularis. About 200 participants will receive either the drug or a placebo for 24 weeks. The main goal is to see if itching improves by at least 4 points on a 0-10 scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Stapokibart injection
- What this could lead to
- If successful, this could provide a new treatment option to reduce severe itching and clear skin nodules in people with prurigo nodularis.
- What could go wrong
- This is a single Phase 3 trial with 200 participants. Results may not apply to everyone, and side effects or lack of benefit are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRURIGO NODULARIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Hospital of China Medical University
Shenyang, Liaoning, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a CBD cream soothe Eczema's relentless itch?
- Can a biologic drug quiet the relentless itch of prurigo nodularis?
- Skin disease evolution under the microscope: a 17-Year look at what drives severity
- New drug aimed at calming the itch of prurigo nodularis enters human testing
- New drug offers hope for severe itch from skin lumps
- New shot aims to stop the maddening itch of prurigo nodularis